Medical Affairs / Scientific Communications · oncology & RA programs (tinengotinib, BCI, MSRC) · corpus in Lancet G&H / ASCO
Irvine, California, United States
Work formatOfficeHybridRemoteEverything above is an outside read of where you've been. This is the one block you write yourself — the direction you're steering toward.
Career arc centers on scientific communications and Medical Affairs in oncology/diagnostics, with program corpuses at top venues (Lancet G&H, CCR, ASCO) aligning to LinkedIn-claimed roles at Biotheranostics, Scipher, and consulting. Strength is program familiarity and publications strategy; attribution remains mostly self-reported.
Career trajectory
Read purely by the companies on record — the same shortcut a recruiter takes.
consultant
UNCONFIRMED
senior medical writer
UNCONFIRMED
senior medical writer
publications/medical affairs consultant
UNCONFIRMED
Progression from consulting into senior medical writing roles, then into a director‑level consulting banner in Medical Affairs/scientific communications.
↗ Ascending⚠Most steps are self‑reported on LinkedIn; only a low‑reliability directory mentions Scipher, so independent confirmations are limited.
Consulting on scientific communications and Medical Affairs via WordSmith Consulting Group — oncology diagnostics manuscripts, congress materials, and SOPs.
I help biotech, diagnostics, and medtech teams turn complex clinical and real‑world evidence into clear manuscripts, congress abstracts/posters, and compliant SOPs. I’ve worked across oncology and immunology, aligning publications with regulatory and commercial timelines. I can map publication plans to study pipelines, manage author/review workflows, and translate data into venue‑appropriate narratives (e.g., Lancet‑class journals and ASCO/ESMO).
›Design a publications plan from first data cut to submission
›Structure a Lancet/NEJM‑style results manuscript
›Stand up a compliant SOP for manuscripts and congress materials
Program evidence is strong: the tinengotinib (TT‑00420) cholangiocarcinoma program shows peer‑reviewed outputs at Lancet Gastroenterology & Hepatology (Feb 2026), Clinical Cancer Research (2026), and ASCO abstracts, aligning with his claimed scope in oncology communications. He led medical writing/publication strategy at Scipher Medicine on the MSRC in rheumatoid arthritis, a corpus with decision‑impact and budget‑impact publications and ongoing corporate updates. Earlier, at Biotheranostics (a Hologic company), he worked on Breast Cancer Index communications; key trials and correlatives (aTTom 2019; Trans‑aTTom 2022) match the stated focus areas. Today he consults via WordSmith Consulting Group, with LinkedIn noting clients like TransThera and J&J MedTech; local DBA/licensing records are portal‑gated and yielded no indexable hits. This profile reads as a low‑footprint, publications‑heavy operator whose program corpus checks out; by‑name acknowledgments and degree verifications would materially strengthen attribution.
An outside read of the profile based on available evidence — what's strong, the one thing to tighten, and what else surfaced.
Reads as a publications‑focused Medical Affairs professional with credible program footprints in oncology and diagnostics. The strongest signals are the existence and timing of program outputs at high‑signal venues (Lancet G&H, CCR, ASCO; R&T; BCR) that match the LinkedIn narrative. The weak side is attribution: most claims are LinkedIn‑only, with county/business/education confirmations gated or collision‑prone, and no by‑name credits located.
Tinengotinib, BCI, and MSRC all have peer‑reviewed/public conference outputs at the stated venues and dates, matching the LinkedIn scope.
High‑signal journals/conferences match scope
Lancet G&H (2026), CCR (2026), ASCO (2026) corroborate the oncology program timeline.
Diagnostics corpus corroboration
MSRC publications (R&T 2023; budget impact 2021) and Scipher’s publications page show sustained activity.
BCI publications present
aTTom (2019) and Trans‑aTTom (2022) align with the claimed Biotheranostics focus.
Most roles and education are LinkedIn‑only; no indexable DBA record and no by‑name acknowledgments on program papers.
UCSD namesake collision risk A prominent UCSD infectious‑diseases researcher named David ‘Davey’ M. Smith appears in results — a different person.
Program PR exists for tinengotinib TransThera publicly announced Lancet publications via PRNewswire.
Local records are portal‑restricted Orange County FBN/RecorderWorks and Irvine business license lookups are interactive; nothing indexable surfaced for the DBA.
Web sources + resume claims · 3 roles need confirmation
WordSmith Consulting Group — Consultant
0 of 1 · Ask →2024-03 — Present
Consulting banner for scientific communications/Medical Affairs; LinkedIn cites J&J MedTech SOPs (cardiac electrophysiology) and TransThera’s tinengotinib program; program outputs appeared at Lancet G&H 2026 and ASCO 2026 (no by‑name credit found).
Scipher Medicine — Senior Medical Writer
Verified · 4 sources2023-03 — 2024-03
Medical writing/publications strategy on MSRC in rheumatoid arthritis; publications include R&T 2023 and related MSRC utility/economic analyses; directory listing provides weak third‑party footprint.
Biotheranostics, Inc. (a Hologic company) — Senior Medical Writer
Verified · 3 sources2021-02 — 2023-03
Publications strategy for BCI/CancerTYPE ID; program outputs include aTTom biomarker validation (2019) and Trans‑aTTom correlatives (2022).
Gerson Lehrman Group — Consultant
0 of 1 · Ask →2016-08 — 2021-02
Biomedical/diagnostic consulting assignments via GLG (per LinkedIn).
Acumen Biomedical Consulting — Senior Consultant
0 of 1 · Ask →2016-08 — 2021-02
Biomedical/diagnostic consulting (per LinkedIn).
Multikinase inhibitor program in cholangiocarcinoma; supported publications (per LinkedIn). Corpus includes Lancet G&H 2026, CCR 2026, and ASCO 2026 outputs; TransThera issued PR on Lancet.
Publication strategy and medical writing for MSRC in RA; independent R&T article and Scipher’s publications feed corroborate activity.
Communications for BCI across manuscripts and congress deliverables; corpus corroborated by peer‑reviewed publications (no by‑name credit for this subject).
Tinengotinib program received PR coverage when TransThera announced Lancet publications (program‑level mention; does not name this individual).
Each read carries a compliment and a tension, with its proof right beside it. It gets sharper as you go.
University of California San Diego
PhD · Neurosciences
Claimed on LinkedIn; no uniquely attributable thesis/department page located in this sweep.
San Diego State University
Master’s degree · Computer Science
GOVERNMENT FILINGS (4)
PRESS & INTERVIEWS (14)
CORPORATE & PRODUCT (1)
VERIFICATION CHECKS — RAN CLEAN (1)
SOCIAL & DIRECTORIES (1)
David Smith works as Consultant at WordSmith Consulting Group, based in Irvine, California, United States.
David Smith is a medical affairs director known for work across tinengotinib, BCI and MSRC programs.
Consulting on scientific communications and Medical Affairs via WordSmith Consulting Group — oncology diagnostics manuscripts, congress materials, and SOPs.
David Smith has worked at 5 companies on record:
Projects and ventures David Smith is behind:
Skills listed on David Smith's profile: medical affairs director. I help biotech, diagnostics, and medtech teams turn complex clinical and real‑world evidence into clear manuscripts, congress abstracts/posters, and compliant SOPs. Can teach: Design a publications plan from first data cut to submission; Structure a Lancet/NEJM‑style results manuscript; Stand up a compliant SOP for manuscripts and congress materials.
David Smith is open to consulting engagements, publications strategy, medical writing and SOP development.
David Smith's education:
Public mentions of David Smith:
This profile is assembled from 21 public sources, last aggregated 2026-09-22. Every fact carries a label: Verified (backed by two or more independent sources), Vouched (confirmed by a person who worked with them) or Self-reported. 5 facts are confirmed by cited sources. It is a public-source professional profile, not a background check.
Controlled by David Smith
A registered account is linked to this profile — a living profile a real person maintains, not a passive scrape.
